# Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer

> **NCT04612894** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 31 (estimated)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** Camrelizumab and Apatinib
- **PROCEDURE:** surgery
- **PROCEDURE:** core needle biopsy

## Key facts

- **NCT ID:** NCT04612894
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-01
- **Primary completion:** 2022-12-01
- **Final completion:** 2023-12-31
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2020-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04612894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04612894, "Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04612894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*